Company: VERA
Filing Date: 2025-04-03
Form Type: DEF 14A
Source: 0001140361-25-012034
Chunk: 64

Company: Vera Therapeutics, Inc.
Filing Date: 2025-04-03
Form: DEF 14A
Chunk 64
---
14,999,999 |
| Longitude Venture Partners IV, L.P.(2)        |     |         1,714,285 |     |    $11,999,995 |
| Sofinnova Venture Partners X, L.P.(3)         |     |           285,714 |     |     $1,999,998 |
| Sean Grant                                    |     |            14,285 |     |        $99,995 |

| (1) | Entities affiliated with Fidelity Management & Research Company LLC collectively beneficially owned more than 5% of our outstanding capital stock. |

| (2) | Patrick Enright is a managing member of Longitude Capital Partners IV, LLC, the general partner of Longitude Venture Partners IV, L.P. and a member of our Board. |

| (3) | Maha Katabi, Ph.D., is a general partner at Sofinnova Venture Partners X, L.P. and a member of our Board. |

Participation in January 2024 Follow-on Public Offering In January 2024, we entered into an underwriting agreement (“January 2024 Underwriting Agreement”) with J.P. Morgan Securities LLC, Cowen and Company, LLC and Evercore Group L.L.C., as representatives of the several underwriters, relating to a follow-on underwritten public offering of shares of our Class A common stock (“January 2024 Follow-on Offering”). Pursuant to the January 2024 Underwriting Agreement, we issued and sold an aggregate of 9,274,194 shares of our Class A common stock to the underwriters, including 1,207,677 shares of

43

TABLE OF CONTENTS

Class A common stock that we issued and sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares in connection with the January 2024 Follow-on Offering, at a price to the public of $31.00 per share. Our January 2024 Follow-on Offering closed on January 29, 2024. Certain holders of more than 5% of our capital stock (including shares of Class A common stock acquired in the offering) purchased shares of our Class A common stock from the underwriters in the January 2024 Follow-on Offering at the offering price of the shares to the public. The following table sets forth the number of shares of our Class A common stock purchased and the aggregate cash purchase price paid by each of these stockholders.

| Name                                          |     | Shares of Class A